Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer ; volume:69 ; number:3 ; day:31 ; month:12 ; year:2019 ; pages:355-364 ; date:3.2020
Cancer immunology immunotherapy ; 69, Heft 3 (31.12.2019), 355-364, 3.2020
- Creator
-
Bains, Simer J.
Abrahamsson, Hanna
Flatmark, Kjersti
Dueland, Svein
Hole, Knut H.
Seierstad, Therese
Redalen, Kathrine Røe
Meltzer, Sebastian
Ree, Anne Hansen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-019-02458-x
- URN
-
urn:nbn:de:101:1-2020052100102504320548
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bains, Simer J.
- Abrahamsson, Hanna
- Flatmark, Kjersti
- Dueland, Svein
- Hole, Knut H.
- Seierstad, Therese
- Redalen, Kathrine Røe
- Meltzer, Sebastian
- Ree, Anne Hansen
- SpringerLink (Online service)
Other Objects (12)
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
Oxaliplatin-Associated Amaurosis Fugax
Oxaliplatin-induced lung fibrosis
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
Novel autoantigens immunogenic in COPD patients
PEPOP: Computational design of immunogenic peptides
Peptide Aggregation Induced Immunogenic Rupture (PAIIR)
Immunogenic Determinants of Coagulation Factor VIII
Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
Oxaliplatin-Associated Amaurosis Fugax
Oxaliplatin-induced lung fibrosis
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
Novel autoantigens immunogenic in COPD patients
PEPOP: Computational design of immunogenic peptides
Peptide Aggregation Induced Immunogenic Rupture (PAIIR)
Immunogenic Determinants of Coagulation Factor VIII
Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
Oxaliplatin-Associated Amaurosis Fugax
Oxaliplatin-induced lung fibrosis
Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer (Adv. Sci. 1/2023)
Novel autoantigens immunogenic in COPD patients
PEPOP: Computational design of immunogenic peptides
Peptide Aggregation Induced Immunogenic Rupture (PAIIR)
Immunogenic Determinants of Coagulation Factor VIII